Prednisolone reduces TNF-α release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4239-4243

  Walz, Annette ^a   Andratschke, Michaela ^b   Wollenberg, Barbara ^a   Lindhofer, Horst ^c   Zeidler, Reinhard ^b,d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TRION Pharma GmbH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Immune therapy; Multicellular tumor spheroids; Trifunctional bispecific antibody

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY BIUII; CYTOKINE; GLUCOCORTICOID; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MULTICELLULAR SPHEROID; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SOLID TUMOR; SPHEROID CELL; THREE DIMENSIONAL IMAGING;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; MICE; PREDNISOLONE; RATS; SPHEROIDS, CELLULAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27944440427     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Belani R and Weiner GJ: T cell activation and cytokine production in anti-CD3 bispecific antibody therapy. J Hematother 4: 395-402, 1995.
2. Michon J, Perdereau B, Brixy F, Moutel S, Fridman WH and Teillaud JL: In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody. Eur J Cancer 4: 631-636, 1995.
3. Renner C, Hartmann F and Pfreundschuh M: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 45: 184-186, 1997.
4. Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van De Winkel JG and Valerius T: Triggering FC alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 165: 5954-5961, 2000.
5. Lindhofer H, Menzel H, Günther W, Hühner L and Thierfelder S: Bispecific antibodies target operationally tumor specific antigens in two leukemia relapse models. Blood 88: 4651, 1996.
6. Lindhofer H, Mocikat R, Steipe B and Thierfelder S: Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219-225, 1995.
7. Ruf P and Lindhofer H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534, 2001.
8. Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B and Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261-266, 2000.
9. Zeidler R, Reisbach G, Lang S, Wollenberg B, Chaubal S, Schmitt B and Lindhofer H: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 1246-1252, 1999.
10. Riesenberg R, Buchner A, Pohla H and Lindhofer H: Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49: 911-917, 2001.
11. Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B and Walz A: TNF alpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 21: 3499-3503, 2001.
12. Walz A, Mack B, Schmitt B, Gires O, Wollenberg B and Zeidler R: Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids. Anticancer Res 24: 887-894, 2004.
13. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177-184, 1988.
14. Bjork P, Jonsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M and Kalland T: Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 268: 24232-24241, 1993.
15. Quak JJ, Balm AJ, van Dongen GA, Brakkee JG, Scheper RJ, Snow GB and Meijer CJ: A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol 136: 191-197, 1990.
16. Hogan MM and Vogel SN: Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins. J Immunol 141: 4196-4202, 1988.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.